ArticleEndocrine connections2025
Metformin reverts aortic calcifications and elastin loss induced by an experimental metabolic syndrome.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic-inflammatory memory: the common pathological basis and therapeutic targets of metabolic syndrome.Reviews in endocrine & metabolic disorders · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) is associated with osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs) and accumulation of arterial calcifications (ACs). Metformin (MET) inhibits this transdifferentiation in vitro. Here, we evaluate the in vivo efficacy of oral MET to reduce AC in a model of MetS. Twenty young male Wistar rats were divided into two groups: one received water and the other received water plus 20% fructose to induce MetS. After 14 days, and for another 4 weeks, MET (100 mg/kg per day) was added to half of each group's drinking source, thus C (water), F (fructose), M (MET) and FM (fructose + MET). Serum and adipose tissue were collected. Aortas were dissected for histomorphometric and immunohistochemical analysis, ex vivo calcification studies and isolation of VSMCs to measure their alkaline phosphatase activity (ALP), collagen production, extracellular mineralization, gene expression of RUNX2 and receptor for advanced glycation end-products (AGEs) (RAGE), and elastic fiber production. F group showed parameters compatible with MetS. Aortic tunica media from F showed decreased elastic-to-muscular layer ratio, increased collagen content and increased levels of the AGEs structure carboxymethyl-lysine. Aortic arches from F presented a tendency for higher ex vivo calcification. VSMCs from F showed increased ALP, collagen secretion, mineralization and expression of RUNX2 and RAGE, and decreased elastic fiber production. All these effects were reverted by MET cotreatment (FM group). In vitro, AGEs-modified bovine serum albumin upregulated RAGE expression of control VSMCs, and this was prevented by MET in an AMP kinase-dependent manner. Thus, experimental MetS induces RAGE upregulation and osteogenic transdifferentiation of aortic VSMCs curbed by oral treatment with MET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.